Abstract:CAR‐T‐cell therapy has shown remarkable promise in cancer treatment but faces significant resistance challenges. This review examines strategies to overcome resistance by targeting apoptotic pathways, including novel combination therapies and CAR constructs. Additionally, it highlights the impact of the tumor microenvironment and the potential of combining strategies to improve CAR‐T cell function and infiltration into tumors. Background Chimeric antigen receptor (CAR)‐T‐cell therapy has transformed cancer treatment, leading to remarkable clinical outcomes. However, resistance continues to be a major obstacle, significantly limiting its efficacy in numerous patients. Objectives This review critically examines the challenges associated with CAR‐T‐cell therapy, with a particular focus on the role of apoptotic pathways in overcoming resistance. Methods We explore various strategies to sensitize tumor cells to CAR‐T‐cell‐mediated apoptosis, including the use of combination therapies with BH3 mimetics, Mcl‐1 inhibitors, IAP inhibitors, and HDAC inhibitors. These agents inhibit anti‐apoptotic proteins and activate intrinsic mitochondrial pathways, enhancing the susceptibility of tumor cells to apoptosis. Moreover, targeting the extrinsic pathway can increase the expression of death receptors on tumor cells, further promoting their apoptosis. The review also discusses the development of novel CAR constructs that enhance anti‐apoptotic protein expression, such as Bcl‐2, which may counteract CAR‐T cell exhaustion and improve antitumor efficacy. We assess the impact of the tumor microenvironment (TME) on CAR‐T cell function and propose dual‐targeting CAR‐T cells to simultaneously address both myeloid‐derived suppressor cells (MDSCs) and tumor cells. Furthermore, we explore the potential of combining agents like PPAR inhibitors to activate the cGAS‐STING pathway, thereby improving CAR‐T cell infiltration into the tumor. Conclusions This review highlights that enhancing tumor cell sensitivity to apoptosis and increasing CAR‐T cell cytotoxicity through apoptotic pathways could significantly improve therapeutic outcomes. Targeting apoptotic proteins, particularly those involved in the intrinsic mitochondrial pathway, constitutes a novel approach to overcoming resistance. The insights presented herein lay a robust foundation for future research and clinical applications aimed at optimizing CAR‐T cell therapies.

The role of CD95 in modulating CAR T-cell therapy: Challenges and therapeutic opportunities in oncology

Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR‐T‐Cell Therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

CAR T cells in solid tumors: challenges and opportunities

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Targeting the Immune-Suppressive Tumor Microenvironment to Potentiate CAR T Cell Therapy

A long way to the battlefront: CAR T cell therapy against solid cancers.

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Strategies for Dodging the Obstacles in CAR T Cell Therapy

CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Prospects and challenges for use of CAR T cell therapies in solid tumors

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures